Declining reimbursement remains the number one concern of practicing urologists, according to findings from the 8th installment of Urology Times' exclusive State of the Specialty survey.
Building a practice takes time and effort, but becoming an active member of your new community is important as well.
Data from phase III studies of collagenase clostridium histolyticum (CCH [XIAFLEX]) showed that the agent met primary endpoints related to Peyronie’s disease (PD) curvature and symptoms, and that it is effective and safe in certain subgroups of men with PD, according to Auxilium Pharmaceuticals, Inc.
When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over definitive treatment, according to researchers from Thomas Jefferson University in Philadelphia who developed the program.
Ceftolozane/tazobactam, an investigational antibiotic, showed positive top-line results in a pivotal phase III clinical trial of the drug’s use in complicated urinary tract infections, Cubist Pharmaceuticals, Inc. reported.